Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) issued its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA traded up $0.03 during trading on Friday, reaching $2.37. The company had a trading volume of 2,288,443 shares, compared to its average volume of 2,997,985. The firm’s fifty day moving average is $2.88 and its 200 day moving average is $3.35. The firm has a market capitalization of $709.48 million, a PE ratio of -4.47 and a beta of 2.30. Sana Biotechnology has a twelve month low of $2.22 and a twelve month high of $5.49.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SANA. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Bank of America dropped their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 14th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.60.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.